The NIH is enrolling a 50+ patient trial. ASH is expensive (biopsies, etc.). This is a trial that is costing the NIH several $millions. To suggest that the trial was simply "rubber stamped" because of the PI is nonsensical. These things are reviewed by committees, the key criteria being scientific merit and potential impact on patients.
BTW - The NIH ran Intercept's Phase II trial (FLINT). Just saying.
"The FLINT trial (Clinical Trials No. NCT01265498(link is external)) was supported by the NIDDK, National Cancer Institute and National Center for Advancing Translational Sciences, all part of NIH. Intercept Pharmaceuticals, Inc. provided partial funding and supplies."
IMC Price at posting:
36.0¢ Sentiment: None Disclosure: Held
